Pacific Biosciences of California, Inc. (PACB)
PacBio Aims to Expand Multiomic Capabilities Via Latest Innovations
PACB unveils new SPRQ-Nx chemistry to cut sequencing costs and boost multiomic features on Revio and Vega.
PacBio Stock Dips Despite Announcing Expanded Partnership With seqWell
PACB expands seqWell partnership to enhance its sequencing workflow offerings with a new multiplexing kit.
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.52, marking a +2.01% move from the previous day.
PacBio Enters Carrier Screening Market With PureTarget Expansion
PACB expands its PureTarget portfolio, streamlining carrier screening with HiFi sequencing to meet rising global demand.
Pacific Biosciences of California, Inc. (PACB) Q2 2025 Earnings Call Transcript
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Christian O. Henry - President, CEO & Director James R.
PacBio Stock Up on Q2 Earnings & Revenue Beat Estimates, Margin Rises
PACB stock jumps after Q2 results beat estimates, with narrow losses, rising margins, and strong global demand.
Pacific Biosciences (PACB) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Pacific Biosciences (PACB) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.2 per share a year ago.
Stay Ahead of the Game With Pacific Biosciences (PACB) Q2 Earnings: Wall Street's Insights on Key Metrics
Beyond analysts' top-and-bottom-line estimates for Pacific Biosciences (PACB), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Pacific Biosciences of California (PACB) Suffers a Larger Drop Than the General Market: Key Insights
Pacific Biosciences of California (PACB) reached $1.54 at the closing of the latest trading day, reflecting a -6.1% change compared to its last close.
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know
The latest trading day saw Pacific Biosciences of California (PACB) settling at $1.5, representing a +1.35% change from its previous close.
Here's Why You Should Add PacBio Stock to Your Portfolio Now
PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset macroeconomic concerns and drive 2025 growth.
